Format

Send to

Choose Destination
Trends Biotechnol. 2013 Nov;31(11):612-20. doi: 10.1016/j.tibtech.2013.07.002. Epub 2013 Aug 7.

Toward aggregation-resistant antibodies by design.

Author information

1
Center for Biotechnology & Interdisciplinary Studies, Department of Chemical & Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.

Abstract

Monoclonal antibodies are attractive therapeutics for treating a wide range of human disorders due to their exquisite binding specificity and high binding affinity. However, a limitation of antibodies is their highly variable and difficult-to-predict propensities to aggregate when concentrated during purification and delivery. Despite the large size and complex structure of antibodies, recent findings suggest that antibody solubility can be dramatically improved using rational design methods in addition to conventional selection methods. Here, we review key advances and unmet challenges in engineering the variable and constant regions of antibody fragments and full-length antibodies to resist aggregation without reducing their binding affinity. These experimental and computational discoveries should accelerate the development of robust algorithms for designing aggregation-resistant antibodies.

KEYWORDS:

Fab; Fv; IgG; V(H); V(L); antibody engineering; bispecific; complementarity-determining region (CDR); monoclonal antibody; scFv; solubility; variable domain

PMID:
23932102
DOI:
10.1016/j.tibtech.2013.07.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center